Andrew H Limper

List of Publications by Year
in descending order

163 papers	9,245 citations	53794 45 h-index	43889 91 g-index
168 all docs	168 docs citations	168 times ranked	8678 citing authors

#	Article	IF	Citations
1	EphA2 Is a Lung Epithelial Cell Receptor for Pneumocystis Î²-Glucans. Journal of Infectious Diseases, 2022, 225, 525-530.	4.0	10
2	Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients. Stem Cell Research and Therapy, 2022, 13, 45.	5.5	1
3	Gene expression in lung epithelial cells following interaction with Pneumocystis carinii and its specific life forms yields insights into host gene responses to infection. Microbiology and Immunology, 2022, 66, 238-251.	1.4	4
4	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 97.	3.6	7
5	Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis. Respiratory Research, 2022, 23, 91.	3.6	16
6	Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9. Drugs in R and D, 2022, 22, 165-173.	2.2	1
7	Grading Bleomycinâ€Induced Pulmonary Fibrosis in ex vivo Mouse Lungs Using Ultrasound Image Analysis. Journal of Ultrasound in Medicine, 2021, 40, 763-770.	1.7	2
8	Patient-reported quality of life in fibrotic interstitial lung disease: novel assessments of self-management ability and affect. ERJ Open Research, 2021, 7, 00011-2021.	2.6	1
9	Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study. BMJ Open, 2021, 11, e044010.	1.9	5
10	Deployment of an Interdisciplinary Predictive Analytics Task Force to Inform Hospital Operational Decision-Making During the COVID-19 Pandemic. Mayo Clinic Proceedings, 2021, 96, 690-698.	3.0	9
11	Antifungal Prophylaxis for Adult Recipients of Veno-Venous Extracorporeal Membrane Oxygenation: A Cautionary Stance During the COVID-19 Pandemic. ASAIO Journal, 2021, 67, 611-613.	1.6	3
12	Survey of the Transcription Factor Responses of Mouse Lung Alveolar Macrophages to Pneumocystis murina. Pathogens, 2021, 10, 569.	2.8	1
13	Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reactionâ€based diagnosis in patients receiving bendamustine. Cancer Medicine, 2021, 10, 5120-5130.	2.8	2
14	Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications. BMC Pulmonary Medicine, 2021, 21, 239.	2.0	6
15	Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1121-1128.	3.2	37
16	Factors Associated With Severe COVID-19 Infection Among Persons of Different Ages Living in a Defined Midwestern US Population. Mayo Clinic Proceedings, 2021, 96, 2528-2539.	3.0	16
17	Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib. Cells, 2021, 10, 3502.	4.1	6
18	Additional C-type lectin receptors mediate interactions with Pneumocystis organisms and major surface glycoprotein. Journal of Medical Microbiology, 2021, 70, .	1.8	3

#	Article	IF	Citations
19	Current State of Carbohydrate Recognition and C-Type Lectin Receptors in Pneumocystis Innate Immunity. Frontiers in Immunology, 2021, 12, 798214.	4.8	2
20	Preadmission Corticosteroid Therapy and the Risk of Respiratory Failure in Adults Without HIV Presenting With Pneumocystis Pneumonia. Journal of Intensive Care Medicine, 2020, 35, 1465-1470.	2.8	5
21	An ex vivo technique for quantifying mouse lung injury using ultrasound surface wave elastography. Journal of Biomechanics, 2020, 98, 109468.	2.1	5
22	Unsupervised machine learning for the discovery of latent disease clusters and patient subgroups using electronic health records. Journal of Biomedical Informatics, 2020, 102, 103364.	4.3	56
23	SIRT7â€mediated modulation of glutaminase 1 regulates TGFâ€Î²â€induced pulmonary fibrosis. FASEB Journal, 2020, 34, 8920-8940.	0.5	25
24	Targeting CARD9 with Small-Molecule Therapeutics Inhibits Innate Immune Signaling and Inflammatory Response to Pneumocystis carinii Î²-Glucans. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
25	Tissue-resident CD8 ⁺ T cells drive age-associated chronic lung sequelae after viral pneumonia. Science Immunology, 2020, 5, .	11.9	81
26	Pneumocystis carinii Major Surface Glycoprotein Dampens Macrophage Inflammatory Responses to Fungal Î²-Glucan. Journal of Infectious Diseases, 2020, 222, 1213-1221.	4.0	4
27	A critical role for <scp>CARD9</scp> in pneumocystis pneumonia host defence. Cellular Microbiology, 2020, 22, e13235.	2.1	10
28	Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 2622-2629.	1.3	2
29	Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARÎ³-FOXA2-phosphatase signaling. Mucosal Immunology, 2020, 13, 637-651.	6.0	20
30	AIDS-Related Mycoses: Updated Progress and Future Priorities. Trends in Microbiology, 2020, 28, 425-428.	7.7	13
31	Phosphoric Metabolites Link Phosphate Import and Polysaccharide Biosynthesis for Candida albicans Cell Wall Maintenance. MBio, 2020, 11, .	4.1	16
32	Advances in the diagnosis of fungal pneumonias. Expert Review of Respiratory Medicine, 2020, 14, 703-714.	2.5	14
33	IPF pathogenesis is dependent upon TGFÎ² induction of IGFâ€1. FASEB Journal, 2020, 34, 5363-5388.	0.5	36
34	Summary for Clinicians: Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. Annals of the American Thoracic Society, 2019, 16, 1473-1477.	3.2	12
35	Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 535-550.	5.6	122
36	Macrophage PPAR-Î³ suppresses long-term lung fibrotic sequelae following acute influenza infection. PLoS ONE, 2019, 14, e0223430.	2.5	32

#	Article	IF	Citations
37	PD-1 ^{hi} CD8 ⁺ resident memory T cells balance immunity and fibrotic sequelae. Science Immunology, 2019, 4, .	11.9	95
38	Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 168-174.	5.6	102
39	Structural basis for the acetylation of histone H3K9 and H3K27 mediated by the histone chaperone Vps75 in Pneumocystis carinii. Signal Transduction and Targeted Therapy, 2019, 4, 14.	17.1	4
40	Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 348-358.	5.6	20
41	The early proximal Î±Î² TCR signalosome specifies thymic selection outcome through a quantitative protein interaction network. Science Immunology, 2019, 4, .	11.9	21
42	PPAR-Î³ in Macrophages Limits Pulmonary Inflammation and Promotes Host Recovery following Respiratory Viral Infection. Journal of Virology, 2019, 93, .	3.4	81
43	Myeloid C-type lectin receptors that recognize fungal mannans interact with Pneumocystis organisms and major surface glycoprotein. Journal of Medical Microbiology, 2019, 68, 1649-1654.	1.8	14
44	Neonatal hyperoxia promotes asthma-like features through IL-33â€“dependent ILC2 responses. Journal of Allergy and Clinical Immunology, 2018, 142, 1100-1112.	2.9	39
45	The 14th International Workshops on Opportunistic Protists (<scp>IWOP</scp> 14). Journal of Eukaryotic Microbiology, 2018, 65, 934-939.	1.7	4
46	Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome. Chest, 2018, 154, 636-644.	0.8	58
47	Dectin-2 Is a C-Type Lectin Receptor that Recognizes Pneumocystis and Participates in Innate Immune Responses. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 232-240.	2.9	27
48	Multi-omic molecular profiling of lung cancer in COPD. European Respiratory Journal, 2018, 52, 1702665.	6.7	25
49	PositivePneumocystis jiroveciiSputum PCR Results with Negative Bronchoscopic PCR Results in Suspected Pneumocystis Pneumonia. Canadian Respiratory Journal, 2018, 2018, 1-5.	1.6	8
50	Comparison of Respiratory Pathogen Detection in Upper versus Lower Respiratory Tract Samples Using the BioFire FilmArray Respiratory Panel in the Immunocompromised Host. Canadian Respiratory Journal, 2018, 2018, 1-6.	1.6	22
51	Fatty acid synthase is required for profibrotic TGFâ€Î²2 signaling. FASEB Journal, 2018, 32, 3803-3815.	0.5	52
52	Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series. BMC Pulmonary Medicine, 2018, 18, 105.	2.0	26
53	Constructing Node Embeddings for Human Phenotype Ontology to Assist Phenotypic Similarity Measurement. , 2018, , .		5
54	In Search of Clinical Factors That Predict Risk for Pneumocystis jirovecii Pneumonia in Patients without HIV/AIDS. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1467-1468.	5.6	4

#	Article	IF	Citations
55	Binding of Pneumocystis carinii to the lung epithelial cell receptor HSPA5 (GRP78). Journal of Medical Microbiology, 2018, 67, 1772-1777.	1.8	18
56	Characterization of N-Acetylglucosamine Biosynthesis in Pneumocystis species. A New Potential Target for Therapy. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 213-222.	2.9	7
57	Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients. Journal of Thoracic Oncology, 2017, 12, 824-832.	1.1	7
58	Pulmonary Toxicities from Conventional Chemotherapy. Clinics in Chest Medicine, 2017, 38, 209-222.	2.1	28
59	The Role of Infection in Interstitial Lung Diseases. Chest, 2017, 152, 842-852.	0.8	65
60	Safety of IV Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2017, 151, 951-952.	0.8	7
61	When to Consider the Possibility of a Fungal Infection. Clinics in Chest Medicine, 2017, 38, 385-391.	2.1	19
62	Phenylpyrrolidine structural mimics of pirfenidone lacking antifibrotic activity: A new tool for mechanism of action studies. European Journal of Pharmacology, 2017, 811, 87-92.	3.5	6
63	Overview of Treatment Approaches for Fungal Infections. Clinics in Chest Medicine, 2017, 38, 393-402.	2.1	55
64	The Interaction of Pneumocystis with the C-Type Lectin Receptor Mincle Exerts a Significant Role in Host Defense against Infection. Journal of Immunology, 2017, 198, 3515-3525.	0.8	45
65	Differential Macrophage Polarization from Pneumocystis in Immunocompetent and Immunosuppressed Hosts: Potential Adjunctive Therapy during Pneumonia. Infection and Immunity, 2017, 85, .	2.2	39
66	Response. Chest, 2017, 152, 900.	0.8	0
67	Fungal infections in HIV/AIDS. Lancet Infectious Diseases, The, 2017, 17, e334-e343.	9.1	327
68	Diagnosis and Treatment of Fungal Chest Infections. Clinics in Chest Medicine, 2017, 38, xv-xvi.	2.1	0
69	Itraconazole and antiretroviral therapy: strategies for empirical dosing â€“ Author's reply. Lancet Infectious Diseases, The, 2017, 17, 1123-1124.	9.1	1
70	Weighing the risks and benefits ofPneumocystispneumonia prophylaxis in iatrogenically immunosuppressed dermatology patients. International Journal of Dermatology, 2017, 56, e5-e6.	1.0	2
71	Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2017, 4, 118.	2.6	213
72	Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease. Oncotarget, 2016, 7, 44211-44223.	1.8	42

#	Article	IF	Citations
73	Intermittent Courses of Corticosteroids Also Present a Risk forPneumocystisPneumonia in Non-HIV Patients. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	25
74	Profibrotic upâ€regulation of glucose transporter 1 by TGFâ€Î² involves activation of MEK and mammalian target of rapamycin complex 2 pathways. FASEB Journal, 2016, 30, 3733-3744.	0.5	52
75	Low incidence of pneumocystis pneumonia utilizing PCRâ€based diagnosis in patients with Bâ€cell lymphoma receiving rituximabâ€containing combination chemotherapy. American Journal of Hematology, 2016, 91, 1113-1117.	4.1	24
76	Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. International Journal of Dermatology, 2016, 55, 823-830.	1.0	25
77	Fungal, Viral, and Parasitic Pneumonias Associated with Human Immunodeficiency Virus. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 257-266.	2.1	21
78	Evidence for a Pneumocystis carinii Flo8-like transcription factor: insights into organism adhesion. Medical Microbiology and Immunology, 2016, 205, 73-84.	4.8	6
79	Drug-Induced Pulmonary Disease. , 2016, , 1275-1294.e17.		17
80	Evidence for Proinflammatory Î²-1,6 Glucans in the Pneumocystis carinii Cell Wall. Infection and Immunity, 2015, 83, 2816-2826.	2.2	30
81	Developing a clinical trial unit to advance research in an academic institution. Contemporary Clinical Trials, 2015, 45, 270-276.	1.8	26
82	Pathobiology ofPneumocystispneumonia: life cycle, cell wall and cell signal transduction. FEMS Yeast Research, 2015, 15, fov046.	2.3	50
83	Î²-Glucanâ€“Activated Human B Lymphocytes Participate in Innate Immune Responses by Releasing Proinflammatory Cytokines and Stimulating Neutrophil Chemotaxis. Journal of Immunology, 2015, 195, 5318-5326.	0.8	55
84	Pneumocystis. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a019828-a019828.	6.2	41
85	Pneumocystis jirovecii Rtt109, a Novel Drug Target for Pneumocystis Pneumonia in Immunosuppressed Humans. Antimicrobial Agents and Chemotherapy, 2014, 58, 3650-3659.	3.2	11
86	Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respiratory Research, 2014, 15, 154.	3.6	77
87	Pneumonia. Treatment and Diagnosis. Annals of the American Thoracic Society, 2014, 11, S189-S192.	3.2	17
88	Identification of a Cell-of-Origin for Fibroblasts Comprising the Fibrotic Reticulum in Idiopathic Pulmonary Fibrosis. American Journal of Pathology, 2014, 184, 1369-1383.	3.8	67
89	Idiopathic Pulmonary Fibrosis: Evolving Concepts. Mayo Clinic Proceedings, 2014, 89, 1130-1142.	3.0	117
90	In Replay: Pneumocystis Pneumonia Following Rituximab. Chest, 2014, 145, 664.	0.8	0

#	Article	IF	Citations
91	Clinical Approach and Management for Selected Fungal Infections in Pulmonary and Critical Care Patients. Chest, 2014, 146, 1658-1666.	0.8	10
92	The Pneumocystis Ace2 Transcription Factor Regulates Cell Wall-remodeling Genes and Organism Virulence. Journal of Biological Chemistry, 2013, 288, 23893-23902.	3.4	7
93	Detection of (1, 3)-Î²-d-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia, 2013, 175, 33-41.	3.1	60
94	Characterization of the Pneumocystis carinii Histone Acetyltransferase Chaperone Proteins PcAsf1 and PcVps75. Infection and Immunity, 2013, 81, 2268-2275.	2.2	8
95	Routine Pneumocystis Pneumonia Prophylaxis in Patients Treated With Rituximab?: Response. Chest, 2013, 144, 360.	0.8	1
96	Pneumocystis Pneumonia in Patients Treated With Rituximab. Chest, 2013, 144, 258-265.	0.8	154
97	Glycosphingolipids Mediate Pneumocystis Cell Wall Î²-Glucan Activation of the IL-23/IL-17 Axis in Human Dendritic Cells. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 50-59.	2.9	40
98	Primary alveolar epithelial cell surface membrane microdomain function is required forPneumocystisÎ²-glucan-induced inflammatory responses. Innate Immunity, 2012, 18, 709-716.	2.4	18
99	Executive Summary. Chest, 2012, 142, 1284-1288.	0.8	9
100	Relationship Between Lung Function Impairment and Health-Related Quality of Life in COPD and Interstitial Lung Disease. Chest, 2012, 142, 704-711.	0.8	28
101	Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients. Chest, 2012, 142, e1S-e111S.	0.8	52
102	Drug-Associated Acute Lung Injury. Chest, 2012, 142, 845-850.	0.8	51
103	Chitinases in Pneumocystis carinii pneumonia. Medical Microbiology and Immunology, 2012, 201, 337-348.	4.8	10
104	Update on the diagnosis and treatment ofPneumocystispneumonia. Therapeutic Advances in Respiratory Disease, 2011, 5, 41-59.	2.6	157
105	An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 96-128.	5.6	494
106	Guidelines for the Naming of Genes, Gene Products, and Mutants in the Opportunistic Protists. Journal of Eukaryotic Microbiology, 2011, 58, 537-538.	1.7	3
107	Substrate analysis of the Pneumocystis carinii protein kinases PcCbk1 and PcSte20 using yeast proteome microarrays provides a novel method for Pneumocystis signalling biology. Yeast, 2011, 28, 707-719.	1.7	1
108	Pneumocystis carinii Expresses an Active Rtt109 Histone Acetyltransferase. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 768-776.	2.9	13

#	Article	IF	Citations
109	Pneumocystis carinii Interactions with Lung Epithelial Cells and Matrix Proteins Induce Expression and Activity of the PcSte20 Kinase with Subsequent Phosphorylation of the Downstream Cell Wall Biosynthesis Kinase PcCbk1. Infection and Immunity, 2011, 79, 4157-4164.	2.2	2
110	Pneumocystis cell wall Î²-glucan stimulates calcium-dependent signaling of IL-8 secretion by human airway epithelial cells. Respiratory Research, 2010, 11, 95.	3.6	41
111	Imatinib Treatment for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 604-610.	5.6	345
112	Characterization of the PcCdc42 small G protein from Pneumocystis carinii, which interacts with the PcSte20 life cycle regulatory kinase. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2010, 298, L252-L260.	2.9	13
113	The Changing Spectrum of Fungal Infections In Pulmonary and Critical Care Practice: Clinical Approach To Diagnosis. Proceedings of the American Thoracic Society, 2010, 7, 163-168.	3.5	38
114	Characterization of PCEng2, a Î²-1,3-Endoglucanase Homolog inPneumocystis cariniiwith Activity in Cell Wall Regulation. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 192-200.	2.9	16
115	The Pneumocystis Meiotic PCRan1p Kinase Exhibits Unique Temperature-Regulated Activity. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 714-721.	2.9	7
116	Characterization of a Novel ADAM Protease Expressed byPneumocystis carinii. Infection and Immunity, 2009, 77, 3328-3336.	2.2	4
117	Pneumocystis Pneumonia: Current Concepts in Pathogenesis, Diagnosis, and Treatment. Clinics in Chest Medicine, 2009, 30, 265-278.	2.1	70
118	Pneumocystis PCINT1, a molecule with integrinâ€like features that mediates organism adhesion to fibronectin. Molecular Microbiology, 2008, 67, 747-761.	2.5	32
119	Pneumocystis carinii Exhibits a Conserved Meiotic Control Pathway. Infection and Immunity, 2008, 76, 417-425.	2.2	28
120	Advances in the biology, pathogenesis and identification of Pneumocystis pneumonia. Current Opinion in Pulmonary Medicine, 2008, 14, 228-234.	2.6	32
121	Redefining the Clinical Spectrum of Chronic Pulmonary Histoplasmosis. Medicine (United States), 2007, 86, 252-258.	1.0	48
122	Temozolomide-Associated Organizing Pneumonitis. Mayo Clinic Proceedings, 2007, 82, 771-773.	3.0	15
123	Temozolomide-Associated Organizing Pneumonitis. Mayo Clinic Proceedings, 2007, 82, 771-773.	3.0	15
124	Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nature Reviews Microbiology, 2007, 5, 298-308.	28.6	229
125	A real-time polymerase chain reaction assay for detection of Pneumocystis from bronchoalveolar lavage fluid. Diagnostic Microbiology and Infectious Disease, 2006, 54, 169-175.	1.8	68
126	Surfactant protein D enhancesPneumocystisinfection in immune-suppressed mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L442-L449.	2.9	26

#	Article	IF	Citations
127	PneumocystisCell Wall Î²-Glucans Induce Dendritic Cell Costimulatory Molecule Expression and Inflammatory Activation through a Fas-Fas Ligand Mechanism. Journal of Immunology, 2006, 177, 459-467.	0.8	66
128	Pneumocystis Melanins Confer Enhanced Organism Viability. Eukaryotic Cell, 2006, 5, 916-923.	3.4	8
129	PneumocystisCell Wall Î²-Glucans Stimulate Alveolar Epithelial Cell Chemokine Generation through Nuclear Factor-ÎºBâ€“Dependent Mechanisms. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 490-497.	2.9	98
130	Macrophage Internalization of Fungal Î²-Glucans Is Not Necessary for Initiation of Related Inflammatory Responses. Infection and Immunity, 2005, 73, 6340-6349.	2.2	53
131	Acute Respiratory Failure Due to Pneumocystis Pneumonia in Patients Without Human Immunodeficiency Virus Infection. Chest, 2005, 128, 573-579.	0.8	164
132	Pneumocystis carinii Cell Wall Biosynthesis Kinase Gene CBK1 Is an Environmentally Responsive Gene That Complements Cell Wall Defects of cbk -Deficient Yeast. Infection and Immunity, 2004, 72, 4628-4636.	2.2	28
133	Pneumocystis Pneumonia. New England Journal of Medicine, 2004, 350, 2487-2498.	27.0	946
134	Chemotherapy-induced lung disease. Clinics in Chest Medicine, 2004, 25, 53-64.	2.1	187
135	Imatinib mesylate inhibits the profibrogenic activity of TGF-Î² and prevents bleomycin-mediated lung fibrosis. Journal of Clinical Investigation, 2004, 114, 1308-1316.	8.2	485
136	Melanin-Like Pigments in Pneumocystis carinii. Journal of Eukaryotic Microbiology, 2003, 50, 621-621.	1.7	0
137	Microarray Analysis of Lung Epithelial Responses to Pneumocystis carinii. Journal of Eukaryotic Microbiology, 2003, 50, 629-630.	1.7	2
138	Pneumocystis carinii: Cell Wall P-Glucan-Mediated Pulmonary Inflammation. Journal of Eukaryotic Microbiology, 2003, 50, 646-646.	1.7	13
139	Pneumocystis carinii BCK1 Complements the Saccharomyces cerevisiae Cell Wall Integrity Pathway. Journal of Eukaryotic Microbiology, 2003, 50, 676-677.	1.7	7
140	Pneumocystis carinii BCK1 functions in a mitogenâ€activated protein kinase cascade regulating fungal cellâ€wall assembly. FEBS Letters, 2003, 548, 59-68.	2.8	15
141	Surfactant Protein D-Mediated Aggregation of Pneumocystis carinii Impairs Phagocytosis by Alveolar Macrophages. Infection and Immunity, 2003, 71, 1662-1671.	2.2	52
142	Evidence for a Melanin Cell Wall Component in Pneumocystis carinii. Infection and Immunity, 2003, 71, 5360-5363.	2.2	12
143	Pneumocystis carinii Cell Wall Î²-Glucans Initiate Macrophage Inflammatory Responses through NF-ÎºB Activation. Journal of Biological Chemistry, 2003, 278, 25001-25008.	3.4	107
144	Lung Epithelial Cells and Extracellular Matrix Components Induce Expression of Pneumocystis carinii STE20 , a Gene Complementing the Mating and Pseudohyphal Growth Defects of ste20 Mutant Yeast. Infection and Immunity, 2003, 71, 6463-6471.	2.2	39

#	Article	IF	Citations
145	Pneumocystis carinii Cell Wall Î²-Glucan Induces Release of Macrophage Inflammatory Protein-2 from Alveolar Epithelial Cells via a Lactosylceramide-mediated Mechanism. Journal of Biological Chemistry, 2003, 278, 2043-2050.	3.4	133
146	Characterization of a Lanosterol 14Î±-Demethylase fromPneumocystis carinii. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 232-238.	2.9	23
147	The role of inflammation in respiratory impairment during pneumonia. Seminars in Respiratory Infections, 2003, 18, 40-47.	1.3	20
148	Subtractive Hybridization Analysis of Pneumocystis carinii Gene Activation Induced by Interaction With Lung Epithelial Cells and Matrix. Chest, 2002, 121, 78S-79S.	0.8	5
149	A Gene Complex Mediating Cyst Wall Assembly and Integrity in Pneumocystis carinii. Journal of Eukaryotic Microbiology, 2001, 48, 133s-133s.	1.7	2
150	Pneumocystis carinii Î²-Glucan Induces Release of Macrophage Inflammatory Protein-2 from Primary Rat Alveolar Epithelial Cells via a Receptor Distinct from CDllb/CD18. Journal of Eukaryotic Microbiology, 2001, 48, 157s-157s.	1.7	8
151	Role of Nuclear Factor-kappa B in the Activation of Alveolar Macrophages by Fungal Beta-Glucans. Journal of Eukaryotic Microbiology, 2001, 48, 160s-160s.	1.7	3
152	Carbohydrate Recognition Domain of Surfactant Protein D Mediates Interactions withPneumocystis cariniiGlycoprotein A. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 475-484.	2.9	51
153	Characterization of Pneumocystis carinii PHR1 , a pH-Regulated Gene Important for Cell Wall Integrity. Journal of Bacteriology, 2001, 183, 6740-6745.	2.2	30
154	Differential Regulation of Growth and Checkpoint Control Mediated by a Cdc25 Mitotic Phosphatase from Pneumocystis carinii. Journal of Biological Chemistry, 2001, 276, 835-843.	3.4	26
155	Isolated Pneumocystis carinii Cell Wall Glucan Provokes Lower Respiratory Tract Inflammatory Responses. Journal of Immunology, 2000, 164, 3755-3763.	0.8	143
156	Cell Wall Assembly by Pneumocystis carinii. Journal of Biological Chemistry, 2000, 275, 40628-40634.	3.4	90
157	Pneumocystis cariniiUses a Functional Cdc13 B-Type Cyclin Complex during Its Life Cycle. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 722-731.	2.9	32
158	Stretch induces cytokine release by alveolar epithelial cells in vitro. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L167-L173.	2.9	270
159	Alveolar macrophage interactions with Pneumocystis carinii. Translational Research, 1999, 133, 535-540.	2.3	24
160	Pneumocystis cariniiContains a Functional Cell-division-cycle Cdc2 Homologue. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 297-306.	2.9	51
161	Interactions of parasite and host epithelial cell cycle regulation during Pneumocystis carinii pneumonia. Translational Research, 1997, 130, 132-138.	2.3	40
162	Pneumocystis carinii Pneumonia in Patients Without Acquired Immunodeficiency Syndrome: Associated Illnesses and Prior Corticosteroid Therapy. Mayo Clinic Proceedings, 1996, 71, 5-13.	3.0	574

#	Article	IF	Citations
163	Pneumocystis cariniiPneumonia: Differences in Lung Parasite Number and Inflammation in Patients with and without AIDS. The American Review of Respiratory Disease, 1989, 140, 1204-1209.	2.9	441